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Abstract 
Previous genome-wide association studies (GWAS) have identified several variants associated 
with platelet function phenotypes; however, the proportion of variance explained by the 
identified variants is mostly small. Rare coding variants, particularly those with high potential 
for impact on protein structure/function, may have substantial impact on phenotype but are 
difficult to detect by GWAS. The main purpose of this study was to identify low frequency or 
rare variants associated with platelet function using genotype data from the Illumina 
HumanExome Bead Chip. Three family-based cohorts of European ancestry, including ~4,000 
total subjects, comprised the discovery cohort, and two independent cohorts, one of European 
and one of African American ancestry, were used for replication. Optical aggregometry in 
platelet-rich plasma was performed in all the discovery cohorts in response to adenosine 
diphosphate (ADP), epinephrine, and collagen. Meta-analyses were performed using both gene-
based and single nucleotide variant association methods. The gene-based meta-analysis 
identified a significant association (P=7.13 x 10
-7
) between rare genetic variants in ANKRD26 
and ADP-induced platelet aggregation. One of the ANKRD26 SNVs - rs191015656, encoding a 
threonine to isoleucine substitution predicted to alter protein structure/function, was replicated in 
Europeans. Aggregation increases of ~20-50% were observed in heterozygotes in all cohorts. 
Novel genetic signals in ABCG1 and HCP5 were also associated with platelet aggregation to 
ADP in meta-analyses, although only results for HCP5 could be replicated. The SNV in HCP5 
intersects epigenetic signatures in CD41+ megakaryocytes suggesting a new functional role in 
platelet biology for HCP5. This is the first study to use gene-based association methods from 
SNV array genotypes to identify rare variants related to platelet function. The molecular 
mechanisms and pathophysiological relevance for the identified genetic associations requires 
further study.  
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Platelets are blood cells that are critical to hemostasis after vascular injury, and their activation 
on ruptured atherosclerotic plaque contributes to pathologic thromboses in myocardial infarction 
and stroke
1
. We previously reported that platelet activation in vitro, in the presence and absence 
of antiplatelet therapy, is highly heritable
2, 3
. A number of subsequent genome-wide association 
studies (GWAS) identified several common genetic variants, including those in PEAR1, GP6, 
ADRA2A, and JMJD1C, which were related to platelet function
4, 5
; however, the overall 
proportion of phenotypic variance explained by the identified loci is modest except for GP6 in 
Jones et al
6
. Furthermore, most variants associated with platelet function, thus far, are noncoding, 
which has made it challenging to determine the mechanism(s) by which genotype influences 
phenotype. 
 
Although GWAS have been successful in identifying associations between common genetic 
variants and platelet function phenotypes
4, 7-9
, they are not well-suited to uncover low frequency 
(~1-5% minor allele frequency (MAF)) and rare variants (<1% MAF) that may have larger 
impact on phenotype. These less common variants are of interest when present in coding regions 
because they have greater potential to modify protein function, providing a clearer biological link 
between genetic and phenotypic variation. Indeed, by limiting genetic association analyses to 
exonic variants predicted to alter the gene product, Huffman et al
10
 identified several low-
frequency genetic variants in pathways not previously suspected of involvement in hemostasis. 
In another recent study, exome sequencing was used to discover exome-wide significant 
associations in HYAL2 and GSTZ1 with platelet aggregation in the Framingham Heart Study 
(FHS), with suggestive findings for AR and MAPRE1.
11
 
 
The main objective of this study was to identify uncommon and rare genetic variants in coding 
sequences that are associated with platelet function. To achieve this aim we performed a meta-
analysis of Exome Chip results from 3 family-based cohorts of European ancestry, in which 
platelet aggregation in response to several agonists was well-characterized. We used gene-based 
and single nucleotide variant (SNV) analyses to discover loci not previously known to be related 
to platelet function. Significant associations identified in our discovery meta-analysis were then 
replicated in independent cohorts of European or African American ancestry.  
 
Methods 
Description of study populations 
GeneSTAR: The Genetic Study of Atherosclerosis Risk (GeneSTAR) is an ongoing, prospective 
study designed to determine environmental, phenotypic, and genetic causes of premature 
cardiovascular disease. Participants (n=3,003) were recruited from European- and African-
American families (n=891) identified from probands with a premature coronary disease event 
prior to 60 years of age who were identified at the time of hospitalization in any of 10 Baltimore 
area hospitals. Apparently healthy siblings of probands and offspring of the siblings and 
probands were screened for traditional coronary disease and stroke risk factors as part of a 2 
week trial of platelet function prior to and following aspirin therapy, 81 mg/day, from 2003-
2006
2
. All measures described here were obtained prior to the commencement of aspirin therapy. 
Exclusion criteria included: 1) the presence of any coronary heart disease or vascular thrombotic 
event, 2) any bleeding disorder or any hemorrhagic event in the past (stroke, gastrointestinal 
bleed), 3)  use of any anticoagulants or anti-platelet agents (i.e. warfarin, persantin, clopidogrel), 
4) chronic or acute nonsteroidal anti-inflammatory agents, including COX-2 inhibitors that could 
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not be discontinued, 5) recent active gastrointestinal disorder, 6) current pharmacotherapy for a 
gastrointestinal disorder, 7) pregnancy or risk of pregnancy during the treatment trial, 8) recent 
menorrhagia, 9) known aspirin intolerance or allergic side effects, 10) serious medical disorders, 
including autoimmune diseases, renal or hepatic failure, cancer or HIV-AIDS, 11) chronic or 
acute use of glucocorticosteroid therapy or any drug that may interfere with the measured 
outcomes,  12) serious psychiatric disorders, and, 13) unable to independently make a decision to 
participate. 
 
Framingham Heart Study: The Framingham Heart Study (FHS) is a longitudinal family-based 
study that started to recruit participants of European ancestry in 1948 and now is on its third 
generation of participants. The Original cohort (first generation) contains 5,209 participants, the 
Offspring cohort (second generation), began to recruit in 1971, contains 5,124 participants, and 
the Third Generation cohort, began to recruit in 2002, contains 4,095 participants. In the present 
study we use data from the Offspring cohort
4
 only.   
 
PAPI Study: The Pharmacogenomics of Anti-Platelet Intervention (PAPI) study is a prospective 
cohort trial examining the relation of genetic variants to platelet function at baseline and in 
response to clopidogrel and aspirin. Characteristics of the Old Order Amish European cohort that 
comprise the PAPI study sample have been described previously
12
.  Briefly, Amish participants 
who were over age 20, generally healthy, and agreed to discontinue the use of medications, 
supplements, and vitamins for at least one week prior to study initiation were eligible for 
recruitment. 
 
Caerphilly Prospective Study (CaPS): The CaPS study is a sample of unrelated men of European 
ancestry recruited around the town of Caerphilly, South Wales as described in the past
9
. The 
ADP phenotype used in this study was collected during phase 2 of CaPS. 
 
A fasting blood sample was drawn from all participants in each study. A complete blood count 
and cholesterol levels were determined and low-density lipoprotein cholesterol levels was 
calculated using the Friedewald equation. Hypertension was defined as systolic blood pressure ≥ 
140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, and/or use of prescription blood pressure 
lowering medications.  Diabetes and current smoking status were obtained by self-report. 
 
Each of these studies was approved by their local review board (GeneSTAR- Johns Hopkins 
Institutional Review Board; FHS- Boston University Institutional Review Board; and PAPI- 
University of Maryland Institutional Review Board) and written informed consent was obtained 
from all participants. Approval for the CaPS was granted by the South East Wales Local 
Research Ethics Committee Panel B. 
 
Platelet function tests and phenotype harmonization: 
Methods to assess platelet function in vitro are described in detail elsewhere
4, 12
. All 3 discovery 
cohorts (FHS, GS, PAPI) drew venous blood from fasting participants into citrated (3.2% or 
3.8% in FHS) vacutainer tubes. In PAPI, the first 5mL of blood drawn were discarded. In GS, the 
first 4mL of blood drawn were discarded. All cohorts centrifuged to isolate PRP (180 x g for 15 
min in GS and PAPI, 160 x g for 5 min in FHS). After transferring the PRP additional 
centrifugation was used to isolate PPP (2000 x g for 10 min in GS and PAPI, 2500 x g for 20 min 
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in FHS). All cohorts used no brake on centrifugation steps. In GS and PAPI, platelet counts were 
adjusted to 200,000 platelets/ul with PPP if the count was less than 200,000 platelets/ul. Platelet 
aggregation was assessed by traditional Born light transmission aggregometry using either a 
PAP-4 aggregometer (GS and FHS) or a PAP-8E aggregometer (PAPI) (Bio/Data Corporation, 
Horsham, Pennsylvania) at 37C with siliconized stir bars rotating at 1200 rpm. 
 
Both GS and PAPI sourced their agonists from the Chronolog Corporation (Havertown, 
Pennsylvania) while FHS used collagen agonist from Bio/Data Corporation (Horsham, 
Pennsylvania) and ADP and epinephrine form Sigma Aldrich Corporation (St. Louis, Missouri). 
In GS, platelets were stimulated with ADP (2, 5, 10, and 20 µM), equine tendon-derived Type I 
collagen (1, 2, 5, and 10 µg/ml), epinephrine (2 and 10 µM), or arachidonic acid (1.6 mM). In 
PAPI, platelets were stimulated with the same agonists and concentrations except that 2 µM 
epinephrine was not measured. In FHS, the percent aggregation was determined after adding 
varying concentrations of ADP (0.05, 0.1, 0.5, 1.0, 3.0, 5.0, 10.0 and 15.0 µM) and epinephrine 
(0.01, 0.03, 0.05, 0.1, 0.5, 1.0, 3.0, 5.0 and 10.0 µM), and with a fixed concentration of 
arachidonic acid (5 mg/mL). In GS and PAPI, maximum aggregation within 5 min of agonist 
addition was measured as the percent change in light transmission relative to the PPP control 
from the same sample. In FHS, maximum percent aggregation was similarly calculated after 4 
min for ADP and 5 min for epinephrine. Not all FHS samples were measured at all doses for 
ADP and epinephrine. Depending on responses to entry dose responses for ADP and 
epinephrine, additional higher or lower doses were added to reach at least a half-maximal 
response, or a low dose without a half-maximal response, resulting in different sample sizes at 
different doses. The lowest dose to create a 50% maximal aggregation (EC50) to ADP or 
epinephrine was determined for all samples in this fashion.  Collagen lag time to 1.9 µmol/L of 
calf-skin derived Type I collagen was also determined in FHS. As previously noted the 
distributions of collagen lag times differed somewhat between FHS and GS
4
 which may be a 
factor of differing collagen sources and doses. Platelet aggregation to 0.725 uM ADP (Sigma 
Aldrich Corp, St. Louis, MO) was determined in CaPS using a Rubel-Renaud 
coaguloaggregometer at 37C with stirring at 1100 rpm. In CaPS 30 mL of blood was drawn for 
other uses before fasting blood was drawn into 0.13M sodium citrate vacutainers for the platelet 
studies. After isolation, PRP was diluted to 300,000 platelets/ul in autologous PPP. Primary and 
secondary (maximal after ~2-2.5 min) percent aggregation were measured. 
  
Phenotypes were harmonized across studies such that twelve traits were defined for analysis: two 
low-dose ADP traits, two high-dose ADP traits, two low-dose epinephrine traits, two high-dose 
epinephrine traits, and four collagen traits. Details are shown in Supplemental Table 1. 
 
Exome Chip, genotype calls, and quality control (Q/C): 
Samples were genotyped using the Illumina HumanExome Bead Chip (GeneSTAR and PAPI 
used v1.2; FHS used v1.0) and cluster files were created using GenomeStudio software. 
Genotypes were called using a similar procedure as reported by the Cohorts for Heart and Aging 
Research in Genomic Epidemiology (CHARGE) Consortium Exome Chip effort
13
. The total 
number of variants for analysis was 246,670, including monomorphic variants from autosomes 
and X chromosome. Quality control procedures were similar to those reported in an Exome Chip 
meta-analysis of the Blood Cell Consortium
14
. All variants in each study were aligned to the 
forward strand and an indexed variant call file for subsequent association analyses was generated 
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and checked for allele alignment using the checkVCF package 
(https://github.com/zhanxw/checkVCF). Cohort level association results were QC’d prior to 
meta-analysis using EasyQC software (www.genepi-regensburg.de/easyqc)
15
. 
 
Genotyping and imputation in the Caerphilly Prospective study 
Genotyping in CaPS was done with the Affymetrix UK BioBank array with genotype calling 
using the Affymetrix Axiom Analysis Suite software. After sample quality control procedures 
(excluding duplicate/reference samples, samples with heterozygosity rate >6 standard deviation 
from the mean and possible sex mismatches) and genotyping quality control procedure 
(excluding variants with Hardy Weinberg Equilibrium P<1E-6, minor allele frequency < 1%), 
the final dataset for genotype imputation consisted of 1,184 samples and 646,137 variants. The 
imputation of 22 autosomes was done using the Haplotype Reference Consortium release 1.1, 
2016 reference panel (European ancestry) with the University of Michigan Imputation Server 
(https://imputationserver.sph.umich.edu/index.html).
16
  
 
Statistical analysis 
Inverse normal transformation was applied to all platelet function traits in each cohort. Traits 
were adjusted for age, sex, and population stratification-based principal components. In each 
cohort, the associations of autosomal and X-chromosomal variants with platelet phenotype were 
analyzed by either raremetalworker 
(http://genome.sph.umich.edu/wiki/RAREMETALWORKER) or rvtests 
(http://zhanxw.github.io/rvtests/)
17
 with familial correlation accounted for using a linear mixed 
effects model. The single variant summary statistics and covariance matrices generated from 
raremetalworker and rvtests were used for meta-analysis. All meta-analyses were performed 
separately by two independent analysts (MHC and LRY) and the results obtained were identical. 
 
The discovery cohort consisted of Europeans in the GeneSTAR, FHS, and PAPI studies. Meta-
analyses were used to discover variants associated with the harmonized platelet phenotypes using 
both gene-based and SNV approaches. Meta-analyses were performed using RAREMETAL 
software (http://genome.sph.umich.edu/wiki/RAREMETAL)
18
. Variants were included in meta-
analyses if the genotype call rate was ≥95%, Hardy-Weinberg equilibrium p-values >1x10
-7
, and 
allele frequency among cohorts differed by <0.3. SNV statistics were meta-analyzed using the 
Cochran-Mantel-Haenszel method. Variable threshold (VT) approach and sequence kernel 
association tests (SKAT) implemented in RAREMETAL were used for gene-based tests. VT has 
better power when selected rare variants in a gene have the same effect direction
19
, while SKAT 
has better power when selected variants have different effect directions
20
. For gene-based tests, 
we considered only missense, nonsense, and splice site variants with MAF < 0.01. Bonferroni 
correction was applied to determine genome-wide significant thresholds for gene-based and SNV 
meta-analyses, where the total number of tests was defined by the number of analyzed 
genes/variants for each platelet reactivity trait. The thresholds were ~3.3x10
-6
 for gene-based and 
~4.3x10
-7
 for SNV meta-analyses. When a genome-wide significance signal was identified, 
conditional analyses were conducted (at the meta-analysis level) using RAREMETAL to identify 
independent signals. The selected significant variants were tested for independence in each round 
and the procedure was repeated until there was no new signal. 
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Two independent cohorts were used to replicate variants identified from the discovery meta-
analyses: 1) CaPS, an all-male population sample of European ancestry (for ADP 0.725 uM in 
PRP phenotype) 
9
, and, 2) the GeneSTAR African American cohort (for all phenotypes). For 
CaPS, Haplotype Reference Consortium imputed data (based on HRCr1.1 2016 reference panel) 
were used for replication.  SNVs from genes that met Bonferroni significance in the gene-based 
meta-analysis were selected for replication if the individual SNVs also met nominal significance 
and the variant was predicted by PolyPhen score
21
 and/or SIFT to damage protein 
structure/function. Consistent with previous methods used to replicate rare variants from locus-
based discovery methods, these rare exonic SNVs were selected because of the high probability 
that these variants had a direct impact on protein function
22, 23
.  
 
 
Results 
 
Sample characteristics of the discovery and replication cohorts including coronary heart disease 
risk factors are shown on Table 1. In general, the study cohorts consisted of middle-aged adults, 
approximately half of whom were women (except CaPS which is solely male). 
 
QQ plots with genomic control estimates from cohort level GWAS, SNV meta-analyses and 
gene-based meta-analyses can be found in Supplemental Figure 1, where the results show no 
systematic inflation in our meta-analyses.   
 
Gene-based meta-analyses and relation of rare nonsynonymous coding variants to platelet 
function 
 
Gene-based meta-analyses were used to discover rare exonic variants, in up to 15,478 genes 
associated with platelet function phenotype. Supplemental Table 2 shows top results from the 
gene-based association analysis. Only 2 genes (ANKRD26, ABCG1) met Bonferroni-corrected 
significance for association with platelet function. 
 
Genetic variation in ANKRD26 was significantly associated with low dose ADP-induced platelet 
aggregation using VT gene-based analyses (Table 2). Twelve rare SNVs (cumulative 
MAF=0.012) in ANKRD26, none of which were present in the PAPI cohort, contributed to the 
association (β= 0.619; P=7.13x10
-7
). The MAFs for the 12 SNVs was <0.3% in our European 
sample, and occurrence of the minor alleles of the 12 SNVs appeared sporadically rather than 
clustered within families (Table 2). The individual SNVs in ANKRD26 were independent of 
each other, with maximum pairwise linkage disequilibrium (r
2
) among them of < 6.58x10
-6
 
(Supplemental Table 3), and together they contributed to an overall positive association with 
ADP aggregation. For each SNV present in both cohorts, the direction of effect was the same in 
GeneSTAR and FHS. Five of the variants met nominal significance for association with low 
dose ADP-induced aggregation (Table 2); however, no single variant met Bonferroni threshold 
for genome-wide significance in SNV analyses.  
 
We sought to replicate gene-based findings for specific SNVs identified in ANKRD26 gene. 
Three of the 5 significant SNVs in ANKRD26 were predicted to be possibly or probably 
damaging by PolyPhen score (Table 3). Four of these 5 SNVs were predicted deleterious by 
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SIFT, including the 3 predicted possibly or probably damaging by PolyPhen. Of these 5 SNVs, 
rs191015656 was significantly associated with platelet aggregation to 0.725 uM ADP in CaPS, 
and the direction of effect was the same as that observed in GeneSTAR and FHS. Carriers of one 
copy of the minor allele (A) at rs191015656 had ~17%, ~33%, and ~50% greater aggregation to 
ADP 3 uM, ADP 2 uM, and ADP 0.725 uM phenotype (in FHS, GeneSTAR, CaPS, 
respectively) than GG homozygotes (Fig. 1). This SNV was not present in the GeneSTAR AA or 
PAPI cohorts. The SNV causes a Thr181Ile change in the protein and overlaps the ANK5 protein 
domain according to UniProt annotation. The other SNVs in ANKRD26 did not replicate or were 
not present in CaPS or GeneSTAR African Americans (Table 3). 
 
Three SNVs in ABCG1, each occurring in <0.03% of our sample, contributed to a statistically 
significant gene-based association with high dose ADP-induced platelet aggregation (β= -2.831; 
P=1.92x10
-06
). Pairwise r
2
 indicated no linkage disequilibrium among the SNVs. Overall, the 
variants were associated with reduced ADP aggregation. Two variants met nominal significance 
for association with ADP aggregation (Table 2), but none met genome-wide significant 
threshold in SNV analyses. We attempted to replicate findings from the 2 SNVs in ABCG1 that 
met nominal significance; however, neither SNV could be imputed in CaPS with high confidence 
(for rs151254598 imputation RSqr=0.00683) nor were they present in our GeneSTAR AA cohort 
(Table 3). 
 
SNV meta-analyses and relation of common variants to platelet function 
 
We also meta-analyzed the SNVs present on the Exome Chip to uncover novel variants 
associated with platelet function. After meta-analysis of variants present in 2 or more of the 
discovery samples a total of up to 129,094 SNVs were examined. Supplemental Table 4 shows 
association results for the top 55 SNVs with P<7x10
-06
, excluding the HCP5 and TRIM24 
findings discussed below.  
 
The SNV meta-analysis identified 11 variants in 7 chromosomal regions that were genome-wide 
significantly associated with platelet function phenotypes. All SNVs identified were common- 
the MAF for each was >9% in our meta-analysis cohort of European ancestry. Association 
findings for 5 of the SNVs- rs12566888 in PEAR1, rs1671152 in GP6, rs869244 and rs4545476 
near ADRA2A, rs342293 near PIK3CG, and rs10761731 in JMJD1C- confirm our previous 
reports and are not considered further here (Supplemental Table 5)
4
. Three additional SNVs in 
GP6 were found to be associated with platelet response to collagen (Supplemental Table 4) and 
all were nonsynonymous. However, these SNVs were all in LD (r
2
>0.76) with another SNV in 
GP6- rs1671152- that we previously reported to be associated with platelet response to collagen
4
. 
 
Several of the SNV association findings with platelet activation phenotypes were novel. 
rs2263316, which is an intronic variant in a long non-coding RNA called HLA complex P5 
(HCP5), was associated with platelet aggregation to ADP (Table 4; P= 3.45x10
-07
). The alternate 
allele was related to greater platelet aggregation in the 3 European cohorts included in the meta-
analysis. In the CaPS and GeneSTAR African American replication cohorts, the direction of 
effect for this SNV was the same achieving nominal significance for replication (P=0.044 and 
0.039 for CaPS and GeneSTAR African Americans, respectively; Table 4). Employing 
BLUEPRINT Consortium regulatory annotations, we found that rs2263316 intersects with 
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CD34-CD41+CD42+ megakaryocytic cell peaks for hypermethylation and H3K9me3 histone 
marks, and nearly adjacent to an H3K27me3 peak. The same region is also a DNase hotspot in 
CD14+CD16- monocytes and overlaps H3K27me3 marks in mesenchymal stem cell bone 
marrow. 
 
Novel associations with epinephrine-induced platelet aggregation were identified for an intronic 
variant of TRIM24 (rs1874326) (Table 4). The alternate allele at this locus was associated with 
reduced platelet aggregation to epinephrine in all 3 European cohorts included in the meta-
analyses. However, the finding in European cohorts could not be replicated in GeneSTAR 
African-Americans individuals and epinephrine-induced platelet aggregation was not assessed in 
CaPS. The SNV overlaps CD34-CD41+CD42+ megakaryocytic peaks for hypermethylation, 
H3K27ac and H3K4me1 histones from the BLUEPRINT Consortium. 
 
Discussion 
 
The main finding of this Exome Chip meta-analysis was discovery and replication of an 
association between a rare coding SNV in ANKRD26 and ADP-induced platelet aggregation. 
Additional associations of SNVs in ABCG1 and HCP5 with platelet aggregation were also 
suggested in meta-analyses, with HCP5 findings nominally confirmed in two additional 
population samples. 
 
We previously performed GWAS to identify several common genetic variants associated with 
agonist-induced platelet aggregation
4, 5
. The SNV meta-analysis in this study confirmed these 
previous reports, including the following genetic association findings: PEAR1 with ADP- and 
epinephrine-induced platelet aggregation; JMJD1C with epinephrine-induced platelet 
aggregation; PIK3CG with epinephrine-induced platelet aggregation; ADRA2A with epinephrine-
induced platelet aggregation; and GP6 with collagen-induced platelet aggregation. 
 
To our knowledge, this is the first report describing an Exome Chip-based study to identify the 
genetic basis for variability in platelet function. Advantages of an Exome Chip approach over 
GWAS are greater potential to identify genotype-phenotype associations for rare variants and a 
closer biological connection between genetic variants and alterations in protein 
structure/function. The coverage with Exome Chip design provides a different view of the exome 
than sequencing-based approaches (e.g., with respect to platelet aggregation
11
). While the Exome 
Chip has the limitation that it does not find and call de novo variants, exome sequencing may 
miss variants present on the Exome Chip due to limitations in capture reagent sets and variable 
site coverage.  To enhance our ability to detect biologically relevant rare genetic associations, we 
limited our gene-based analyses to missense, nonsense, and splice site variants with MAF < 0.01. 
A similar approach was used to identify novel variants contributing to platelet count and mean 
platelet volume
14
. Furthermore, we considered the impact of the variant on protein 
structure/function using PolyPhen
21
 and SIFT scores when selecting specific variants for 
replication. 
 
We identified a strong relation between genetic variation in ANKRD26 and platelet aggregation 
to ADP in our gene-based meta-analysis. Several rare variants contributed to this overall gene-
based effect; among these, 5 SNVs were nominally significant in the discovery meta-analysis 
Page 10 of 46
URL: http://mc.manuscriptcentral.com/cpla E-mail: P.Harrison.1@bham.ac.uk
Platelets
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Exome Chip Platelet Agg 
 
and 3 of these 5 were predicted to alter protein structure/function with two prediction programs. 
One of these SNVs- rs191015656- is a single nucleotide substitution of adenine for guanine, 
causing isoleucine to be substituted for threonine in the primary protein structure. The Thr181Ile 
variant we discovered to be associated with increased platelet aggregation is within the fifth 
Ankyrin repeat domain. Ankyrin repeats are often sites of protein-protein interactions.  This 
specific variant was significantly associated with platelet aggregation to ADP in the CaPS 
replication cohort, and greater aggregation to ADP was observed for its heterozygotes in all 
cohorts studied. The magnitude of effect of this genetic variant on aggregation appeared greatest- 
50% higher compared to GG homozygotes- for the cohort treated with the lowest dose of ADP. 
Allelic effects on platelet aggregation may be more likely to be unmasked at low doses of agonist 
where the external stimulus does not overwhelm the endogenous gene effects. This may suggest 
that future studies seeking to map genetic determinants of platelet aggregation in the general 
population may want to include assessment of low agonist doses. 
 
The mechanism underlying an association between genetic variation in ANKRD26 and enhanced 
platelet aggregation to ADP cannot be determined from this study. However, ANKRD26 has 
previously been reported to be involved in thrombopoiesis.  ANKRD26 encodes a 192kD protein 
that is highly expressed in megakaryocytes (MKs)
24
, and several mutations in the 5’ untranslated 
regulatory region (UTR) are associated with a rare form of familial autosomal dominant 
thrombocytopenia
25
. Functional studies indicate transcription factors (RUNX1/FLI1) fail to bind 
the mutated 5’ UTR of ANKRD26 and suppress its expression, and its persistence during MK 
development leads to a reduction in proplatelet formation
26
. It was recently reported that some 
familial mutations in the 5’ UTR of ANKRD26 in subjects with hereditary thrombocytopenia are 
also associated with reduced platelet aggregation to arachidonic acid and epinephrine
27
. 
However, a study of 22 independent individuals with 5’UTR mutations found no specific platelet 
aggregation defect
287
. A recent Exome Chip meta-analysis of >150,000 subjects did not reveal a 
relation between coding variants in ANKRD26 and platelet count or mean platelet volume
14
 and 
an association with platelet aggregation was not investigated. The role of upstream mutations and 
coding mutations may be distinct in their effects on platelet maturation, thrombocytopenia and 
platelet function. Additional studies are needed to elucidate the molecular mechanism for the 
relation between exonic variation in ANKRD26 and platelet aggregation and the clinical 
consequences, if any, of this variation. 
 
ABCG1 encodes an ATP-binding cassette (ABC) transporter known to be involved in cellular 
efflux of high density lipoprotein, suppression of toll-like receptor mediated inflammation, and 
atherosclerosis
29
. ABC transporters are also known to regulate maturation of hematopoietic 
progenitor cells and MKs
29
; however, an association with platelet aggregation has not been 
reported. Although our gene-based meta-analysis suggested an association between genetic 
variation in ABCG1 and ADP-induced aggregation, PolyPhen and SIFT predicted both variants 
we identified to be benign. One of these variants- rs151254598- encoding a glycine to arginine 
substitution, was associated with a reduction in ADP-induced aggregation in CaPS similar in 
direction to the discovery cohort; however, we could not impute this rare SNV in CaPS with 
confidence. Thus, confirmation of this genotype-phenotype association requires additional 
replication. 
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Our SNV meta-analysis identified a common intronic variant in HCP5 associated with ADP-
induced aggregation. We observed modest replication of this finding in CaPS and the 
GeneSTAR AA cohorts (P=0.044 and 0.039, respectively). HCP5 encodes a long non-coding 
RNA within a region that is rich in DNAse I hypersensitivity sites, which are particularly notable 
in cells of hematopoietic origin. Using BLUEPRINT Consortium data, we show direct overlap of 
rs2263316 with CD34-CD41+CD42+ megakaryocytic cell peaks for hypermethylation and 
H3K9me3 histone marks. This SNV is also nearly adjacent to an H3K27me3 peak. These histone 
marks generally reflect repressive regulatory effects and suggest HCP5 may have specific roles 
and expression in megakaryocytes. From public gene expression resources, tissues with the 
highest RNA expression of HCP5 include bone marrow, whole blood, immune cells and spleen.  
Interestingly, SNVs in HCP5 are associated with disease progression and viral load in patients 
with HIV infection, suggesting an immunomodulatory role for HCP5
30
; however, an association 
with platelet function has not previously been described. Additional studies are required to 
confirm this association and determine its molecular basis. 
 
Our study has several limitations. We focused on exonic variants, particularly those affecting 
protein structure/function, to enhance biological plausibility for genotype-phenotype association 
findings; however, we did not study the molecular mechanism for findings and we cannot 
exclude that associations observed are due to LD with ungenotyped exonic, intronic, or 
intergenic variants. Our discovery cohort included ~4,000 subjects of European descent for 
which we had sufficient power to detect an effect for a rare variant (i.e., occurring with 
MAF<0.01) explaining 1% of trait variance with 81.3% power (Supplemental Table 6). Thus, 
we could have missed gene-association findings for variants occurring less frequently or with 
smaller effect size. We examined genetic associations with platelet function in response to ADP, 
epinephrine, and collagen. Although we harmonized platelet phenotypes, heterogeneity of 
phenotypic assessment across studies may have impeded our ability to detect important 
genotype-phenotype associations. Finally, although platelet aggregation phenotypes have been 
reported to be associated with thrombotic outcomes (e.g. myocardial infarction) in human 
subjects
31, 32
, the pathophysiologic relevance of the genotype-phenotype associations identified in 
this report are yet unknown. Strengths of the study include that it is one of the largest genetic 
studies of platelet aggregation to date, and the inclusion of two replication samples of diverse 
origin.  
 
 
In summary, in a gene-based meta-analysis involving ~4,000 individuals of European ancestry, 
we identified a novel association between a rare variant in ANKRD26 (rs191015656) and greater 
platelet aggregation to ADP. A novel association in HCP5 (rs2263316) with greater platelet 
aggregation to ADP was also identified. Supportive evidence for these associations was provided 
in independent replication samples. The molecular mechanism and clinical consequences for 
these gene association findings require further study. 
 
  
Page 12 of 46
URL: http://mc.manuscriptcentral.com/cpla E-mail: P.Harrison.1@bham.ac.uk
Platelets
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Exome Chip Platelet Agg 
 
Tables 
Table 1: Sample characteristics of the study cohorts.  
Table 2: Significant association findings from gene-based meta-analysis in discovery cohorts. 
*Phenotype = ADP low 1; **Phenotype= ADP high 2; MAF= minor allele frequency; Ref= 
reference allele; Alt= alternate allele; Nhet= number of heterozygotes; Nhetfam= number of 
families with at least one heterozygote; direction of effect appears in order -GS/FHS/PAPI,  X = 
variant not present in cohort; ***alternate protein isoforms for ANKRD26 and ABCG1 exist that 
affect some or all of the relative amino acid positions 
Table 3:  Translational effect and replication of gene-based association findings. 
MAF= minor allele frequency; Rsq= imputation accuracy (observed: expected) measure; bold 
highlight denotes significant replication finding; NA = no information available (no allele 
carriers) *alternate protein isoforms for ANKRD26 and ABCG1 exist that affect some or all of 
the relative amino acid positions 
Table 4: Significant novel locus findings and replication from single nucleotide variant analysis. 
Bold highlight denotes significant replication finding; *see Supplemental Table 1 for meta-
analysis phenotype descriptions and mean (SD) in each cohort; **1-sided test statistics are 
reported since replication required a priori the same direction of effect as discovery; Epinephrine 
data was not acquired in CaPS and thus unavailable for replication of the TRIM24 signal 
 
Figure legends 
Figure 1. Impact of genetic variation in ANKRD26 (rs191015656) on ADP-induced platelet 
aggregation in discovery and replication cohorts. Optical aggregation was performed in platelet 
rich plasma in response to ADP. The concentrations of ADP used to induce aggregation (from 
left to right) were as follows: 0.725 uM, 3 uM, and 2 uM, in Caerphilly Prospective Study 
(CaPS), the Framingham Heart Study (FHS), and GeneSTAR (GS), respectively. 
Supplemental Figure 1. QQ plots and genomic enrichment values for all single variant and 
gene-based tests in individual cohorts and meta-analyses.  
 
Supplemental Tables 
Supplemental Table 1. Harmonization of platelet phenotype for meta-analysis. 
Supplemental Table 2. Gene-based analysis suggestive signals (P<1.0E-04). 
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Supplemental Table 3. Linkage disequilibrium calculations among ANKRD26 variants in 
unrelated individuals in FHS. 
Supplemental Table 4. SNV known or suggestive signals (P<7.0E-06). 
Supplemental Table 5. SNV associations confirming prior reported genome-wide significant 
findings
4
. 
Supplemental Table 6. Power analysis for 4,000 individuals with family structure. We used 
SOLAR
33
 to simulate phenotypes conditional on the observed family structures in the FHS 
sample. The phenotypes were simulated to have variance of 1 and polygenic heritability of 0.25. 
We considered the QTL (additive model) with MAF of 0.01, 0.05, 0.1, 0.2, 0.3 and 0.4, and QTL 
variance of 0.0025, 0.005, 0.0075 and 0.01. 1,000 of replicates were used to estimate power for 
each considered scenario. Simulated phenotypes were analyzed using a linear mixed effects 
model implemented in the lmekin function from the coxme R package where a relationship 
coefficient matrix was used to account for familial correlation. 
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Impact of genetic variation in ANKRD26 (rs191015656) on ADP-induced platelet aggregation in discovery 
and replication cohorts. Optical aggregation was performed in platelet rich plasma in response to ADP. The 
concentrations of ADP used to induce aggregation (from left to right) were as follows: 0.725 uM, 3 uM, and 
2 uM, in Caerphilly Prospective Study (CaPS), the Framingham Heart Study (FHS), and GeneSTAR (GS), 
respectively. Individual black points represent platelet values for heterozygotes for rs191015656.  
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Table 1. Sample characteristics of the study cohorts 
 
 Discovery Meta-Analysis Cohorts Replication Cohorts 
 European Ancestry European 
Ancestry 
African 
American 
 GeneSTAR  
N= 1,060 
FHS 
N=2,604 
PAPI 
N=549 
Caerphilly 
N=1,184 
GeneSTAR 
N=613 
Age, mean (SD), yr 42.4 (12.6) 54.4 (9.7) 44.9 (13.8) 56.8 (4.4) 42.2 (12.2) 
Female sex, % 551 (52.0) 1,404 (53.9) 282 (51.4 ) 0 (0) 381 (62.2) 
BMI, mean (SD), kg/m2 28.7 (6.3) 27.4 (4.9) 27.3 (4.9) 26.7 (3.6) 32.2 (8.3) 
HTN, % 263 (24.8) 509 (19.6) 19 (3.5) 668 (56.7) 229 (37.4) 
Diabetes, % 56 (5.3) 161 (6.2) 4 (0.7) 34 (2.9) 67 (11.0) 
LDL cholesterol, mean 
(SD), mg/dL 
125.4 (37.4) 126.5 (32.8) 136.8 (44.3) 144.3 (35.5) 121.6 (38.0) 
Current smoker, % 256 (24.2) 473 (18.2) 52 (9.5) 398 (41.2) 187 (30.5) 
 
BMI= body mass index; HTN = hypertension; LDL= low density lipoprotein 
Page 21 of 46
URL: http://mc.manuscriptcentral.com/cpla E-mail: P.Harrison.1@bham.ac.uk
Platelets
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Table 2.  Significant association findings from gene-based meta-analysis in discovery cohorts. 
gene dbSNPid  chr:pos 
protein 
effect*** 
N MAF Ref Alt Nref Nhet Nalt Nhetfam direction  beta Pvalue 
ANKRD26* 
gene-based 
analysis 0.6193 7.13E-7 
rs61745662 10:27324401 
E992A or 
E993A 4047 0.00049 T G 4043 4 0 4 ++X 1.4682 0.0039 
rs146159734 10:27306678 
C1419Y or 
C1420Y 4047 0.00210 C T 4030 17 0 15 ++X 0.6729 0.0057 
rs139949439 10:27328937 
E777Q or 
E778Q 4047 0.00285 C G 4016 23 0 16 --X -0.5668 0.0071 
rs191015656 10:27381431 T181I 4047 0.00124 G A 4037 10 0 8 ++X 0.8476 0.0080 
rs141748831 10:27329099 
S723R or 
S724R 4047 0.00210 T G 4030 17 0 12 ++X 0.5914 0.018 
rs41304587 10:27324372 
E1002K or 
E1003K 4047 0.00198 C T 4031 16 0 15 ++X 0.4527 0.07 
rs79092403 10:27382639 N111A 4047 0.00025 T C 4045 2 0 1 X+X 1.1681 0.12 
rs201638257 10:27375498 P227S 4047 0.00074 G A 4039 6 0 3 ++X 0.2835 0.51 
rs200100926 10:27382438 Q124L 4047 0.00012 T A 4046 1 0 1 X-X -0.5269 0.60 
rs201461870 10:27350084 V484A 4047 0.00012 A G 4046 1 0 1 -XX -0.5064 0.61 
rs199683454 10:27389253 M1I 4047 0.00012 C T 4046 1 0 1 X+X 0.4922 0.62 
rs28477279 10:27335399 
R622Q or 
R623Q 4047 0.00025 C T 4045 2 0 2 X+X 0.1677 0.81 
ABCG1** 
gene-based 
analysis -2.8314 1.92E-6 
rs151254598 21:43708097 
G358R or 
G369R 3794 0.00026 G A 3792 2 0 2 --X -2.7629 8.30E-5 
rs201983330 21:43708059 
R345Q or 
R356Q 3794 0.00013 G A 3793 1 0 1 -XX -2.9617 0.0029 
rs138056067 21:43697009 
S181L or 
S192L  3794 0.00066 C T 3789 5 0 5 ++X 0.2086 0.64 
*Phenotype = ADP low 1; **Phenotype= ADP high 2; MAF= minor allele frequency; Ref= reference allele; Alt= alternate allele; 
Nhet= number of heterozygotes; Nhetfam= number of families with at least one heterozygote; direction of effect appears in order -
GS/FHS/PAPI, X = variant not present in cohort; ***alternate protein isoforms for ANKRD26 and ABCG1 exist that affect some or 
all of the relative amino acid positions 
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Table 3: Translational effect and replication of gene-based association findings. 
gene dbSNPid 
PolyPhen 
Score 
Predicted effect  
on protein 
SIFT 
score 
Predicted 
effect 
Study Phase/Cohort N REF ALT MAF beta Pvalue Rsq 
ANKRD26 
rs61745662 0.723 
Possibly 
damaging 
0.02 deleterious 
Discovery meta 4047 T G 0.00049 1.4682 0.0039 
 
CaPS 1028 T G 0.00001 -85.7905 0.53 0.983 
GeneSTAR AA 574 T G 0.06882 -0.0040 0.97 
 
rs146159734 0.091 benign 0.73 tolerated 
Discovery meta 4047 C T 0.00210 0.6729 0.0057 
 
CaPS 1028 C T 0.00119 -0.5449 0.42 0.843 
GeneSTAR AA 574 C T 0.00087 -0.8436 0.39 
 
rs139949439 0.998 
Possibly 
damaging 
0.02 deleterious 
Discovery meta 4047 C G 0.00285 -0.5668 0.0071 
 
CaPS 1028 C G 0.00331 0.6620 0.11 0.826 
GeneSTAR AA 574 C G 0.00087 0.4553 0.64 
 
rs191015656 0.904 
Possibly 
damaging 
0 deleterious 
Discovery meta 4047 G A 0.00124 0.8476 0.0080 
 
CaPS 1028 G A 0.00140 1.5643 0.011 0.921 
GeneSTAR AA 574 NA NA NA NA NA 
 
rs141748831 0.372 benign 0.03 deleterious 
Discovery meta 4047 T G 0.00210 0.5914 0.018 
 
CaPS 1028 T G 0.00284 -0.5188 0.23 0.949 
GeneSTAR AA 574 NA NA NA NA NA 
 
ABCG1 
rs151254598 0 benign 0.59 tolerated 
Discovery meta 3794 G A 0.00026 -2.7629 8.3E-5 
 
CaPS 1028 G A 0.00002 -153.752 0.0016 0.007 
GeneSTAR AA 606 NA NA NA NA NA 
 
rs201983330 0.001 benign 0.97 tolerated 
Discovery meta 3794 G A 0.00013 -2.9617 0.0029 
 
CaPS 1028 NA NA NA NA NA NA 
GeneSTAR AA 606 NA NA NA NA NA 
 
 
MAF= minor allele frequency; Rsq= imputation accuracy measure; NA = no information available (no allele carriers)  
Significant replication findings are highlighted 
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Table 4: Significant novel locus findings and replication from single nucleotide variant analysis. 
gene chr:pos dbSNPid snp annotation Trait (uM) Phase Study N AF Nref Nhet Nalt beta pval direction 
HCP5 6:31421297 rs2263316 intronic (overlaps 
CD34-
CD41+CD42+ 
MK cell 
H3K9me3 + 
hypermethylation 
peaks) 
ADP low2* Discovery meta 3697 0.65 480 1614 1602 0.132 3.5E-7 +++ 
ADP 2 Discovery GS 943 0.63 128 443 371 0.090 0.12 + 
ADP EC50 Discovery FHS 2205 0.63 322 1001 882 0.139 9.1E-6 + 
ADP 2 Discovery PAPI 549 0.79 30 170 349 0.164 0.032 + 
ADP 0.725  Replication# CaPS 1028 0.66 127 462 439 0.084 0.044 + 
ADP 2 Replication# AA 574 0.71 56 217 300 0.121 0.039 + 
TRIM24 7:138157390 rs1874326 intronic (overlaps 
CD34-
CD41+CD42+ 
MK cell 
H3K27ac, 
H3K4me1+ 
hypermethylation 
peaks) 
Epi high1* Discovery meta 2730 0.85 57 690 1983 -0.209 1.3E-7 --- 
Epi 10 Discovery GS 1050 0.86 12 261 777 -0.262 1.3E-4 - 
Epi 3 Discovery FHS 1131 0.86 27 260 844 -0.170 4.9E-3 - 
Epi 10 Discovery PAPI 549 0.82 18 169 362 -0.205 0.011 - 
Epi 10 Replication# AA 607 0.85 9 168 430 0.001 0.49 + 
 
highlighted denotes significant replication finding; *see Supplemental Table 1 for meta-analysis phenotype descriptions and mean (SD) 
in each cohort; 
#
one-sided test statistics are reported since replication required a priori the same direction of effect as discovery; 
Epinephrine data was not acquired in CaPS and thus unavailable for replication of the TRIM24 signal 
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Supplemental Table 1: Harmonizing platelet phenotypes for meta-analysis 
Agonist Framingham Phenotype 
N=2,604 
GeneSTAR 
Phenotype 
N=1,060 
PAPI Phenotype 
N=549 
ADP low 1 
mean (SD) 
Max aggregation to 3μM 
67.4% (24.9%) 
Max aggregation to 2μM 
42.8% (26.2%) 
Max aggregation to 2μM 
39.1% (21.7%) 
ADP high 1 
mean (SD) 
Max aggregation to 5μM 
77.4% (18.7%) 
Max aggregation to 10μM 
78.4% (14.3%) 
Max aggregation to 10μM 
68.3% (12.6%) 
ADP low 2 
mean (SD) 
Threshold dose for >50% 
aggregation 
3.3 uM (1.5 uM) 
Max aggregation to 2μM 
42.8% (26.2%) 
Max aggregation to 2μM 
39.1% (21.7%) 
 
ADP high 2 
mean (SD) 
Threshold dose for >50% 
aggregation 
3.3 uM (1.5 uM) 
Max aggregation to 10μM 
78.4% (14.3%) 
Max aggregation to 10μM 
68.3% (12.6%) 
Epi low 1 
mean (SD) 
Max aggregation to 1μM 
57.1% (31.2%) 
Max aggregation to 2μM 
54.0% (33.7%) 
Max aggregation to 10μM 
62.3% (25.2%) 
Epi high 1 
mean (SD) 
Max aggregation to 3μM 
65.9% (28.5%) 
Max aggregation to 10μM 
69.7% (28.6%) 
Max aggregation to 10μM 
62.3% (25.2%) 
Epi low 2 
mean (SD) 
Threshold dose for >50% 
aggregation 
2.0 uM (2.9 uM) 
Max aggregation to 2μM 
54.0% (33.7%) 
Max aggregation to 10μM 
62.3% (25.2%) 
Epi high 2 
mean (SD) 
Threshold dose for >50% 
aggregation 
2.0 uM (2.9 uM) 
Max aggregation to 10μM 
69.7% (28.6%) 
Max aggregation to 10μM 
62.3% (25.2%) 
Collagen 
group1 
mean (SD) 
Lag time to 190 μg/mL* 
81.9 sec (19.9 sec) 
Lag time to 1μg/mL** 
156 sec (90.3 sec) 
Lag time to 1μg/mL** 
58.4 sec (23.9 sec) 
Collagen 
group2 
mean (SD) 
Lag time to 190 μg/mL 
81.9 sec (19.9 sec) 
Lag time to 2μg/mL 
106 sec (63.0 sec) 
Lag time to 2μg/mL 
49.2 sec (16.3 sec) 
Collagen 
group3 
mean (SD) 
Lag time to 190 μg/mL 
81.9 sec (19.9sec ) 
Lag time to 5μg/mL 
71.9 sec (35.8 sec) 
Lag time to 5μg/mL 
38.5 sec (11.1 sec) 
Collagen 
group4 
mean (SD) 
Lag time to 190 μg/mL 
81.9 sec (19.9 sec) 
Lag time to 10μg/mL 
61.8 sec (23.8 sec) 
Lag time to 10μg/mL 
33.1 sec (10.1 sec) 
*Collagen was obtained from Bio-Data Corp (Horsham, PA) 
**Collagen was obtained from Chrono-Log Corp (Havertown, PA) 
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Supplemental Table 2. Gene-based analysis suggestive signals (P<1.0E-04). 
phenotype gene N pval 
no. 
site 
beta se 
direction.burden 
.by.study 
direction.meta 
.single.var 
test 
ADP high 1 ABCG1 3275 3.49E-6 2 -2.417 0.498 --= -- VT 
Epi high 1 ZNF197 2730 7.06E-6 4 1.196 0.258 ++= ++++ VT 
Collagen 1 SPATA4 3753 1.02E-5 1 1.598 0.131 =+= + VT 
Collagen 2 SPATA4 3753 1.02E-5 1 1.598 0.131 =+= + VT 
Collagen 10 SPATA4 3742 1.02E-5 1 1.598 0.131 =+= + VT 
Collagen 3 SPATA4 3753 1.02E-5 1 1.598 0.131 =+= + VT 
Collagen 1 SPATA4 3753 1.02E-5 1 1.598 0.131 =+= + SKAT 
Collagen 2 SPATA4 3753 1.02E-5 1 1.598 0.131 =+= + SKAT 
Collagen 10 SPATA4 3742 1.02E-5 1 1.598 0.131 =+= + SKAT 
Collagen 3 SPATA4 3753 1.02E-5 1 1.598 0.131 =+= + SKAT 
ADP high 1 TPR 3275 1.22E-5 10 -0.019 0.119 +-= -+--+----+ SKAT 
ADP high 2 ZNF610 3794 1.58E-5 5 -0.292 0.086 -+- --++- SKAT 
ADP low 2 ZNF25 3697 1.87E-5 1 2.963 0.479 +== + VT 
ADP low 2 ZNF25 3697 1.87E-5 1 2.963 0.479 +== + SKAT 
Epi high 1 LAPTM4B 2730 1.87E-5 5 1.356 0.306 ++= +++++ VT 
ADP low 1 ANKRD26 4047 2.07E-5 12 0.343 0.103 -+= +++-++-++-++ SKAT 
Collagen 10 COL4A2 3742 2.28E-5 11 -0.708 0.159 --= ----------- VT 
ADP low 1 ABCC9 4047 2.39E-5 4 1.629 0.363 ++= ++++ VT 
Collagen 1 HAUS3 3753 3.68E-5 3 -1.623 0.364 --= --- VT 
ADP low 1 MICU1 4047 4.06E-5 2 -1.538 0.382 --= -- SKAT 
Epi high 1 SLCO2B1 2730 4.09E-5 7 -0.369 0.285 -+= ++----+ SKAT 
Epi high 1 ZNF197 2730 4.63E-5 4 1.196 0.258 ++= ++++ SKAT 
ADP high 1 ZNF610 3275 5.61E-5 6 -0.320 0.089 -+- --+++- SKAT 
ADP high 2 LEFTY1 3794 6.13E-5 1 1.422 0.126 ++= + VT 
ADP high 2 LEFTY1 3794 6.13E-5 1 1.422 0.126 ++= + SKAT 
Epi high 1 RLBP1 2730 6.85E-5 3 0.969 0.272 +++ -++ SKAT 
Collagen 1 SLC6A16 3753 7.04E-5 13 0.329 0.108 +++ +++--+--+--++ SKAT 
Epi low 2 ASIC5 3797 7.21E-5 9 -0.898 0.211 +-= -------+- VT 
ADP high 1 DDX60 3275 7.52E-5 8 0.584 0.175 ++= ++++--++ SKAT 
Epi high 2 RLBP1 3798 8.20E-5 3 0.981 0.238 +++ +++ VT 
ADP high 1 RAB25 3275 8.25E-5 3 -1.118 0.299 =-= +-- SKAT 
Epi high 1 TXNIP 2730 8.39E-5 1 -2.891 0.706 =-= - VT 
Epi low 2 DYNC2H1 3797 8.52E-5 20 0.821 0.187 ++= 
-+-++++++++-
+-+++-++ 
VT 
ADP high 2 GJA9 3794 8.90E-5 3 1.734 0.414 ++= +++ VT 
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Epi high 1 DIRC1 2730 8.91E-5 3 -0.558 0.137 --- --- SKAT 
Epi high 1 RLBP1 2730 9.32E-5 2 1.198 0.295 +++ ++ VT 
ADP low 1 SLC6A17 4047 9.54E-5 3 2.343 0.577 =+= +++ VT 
Epi low 2 LIM2 3797 9.60E-5 3 1.199 0.289 ++= +++ VT 
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Supplemental Table 3. Linkage disequilibrium calculations among ANKRD26 variants in 
unrelated individuals in FHS. 
SNP1 SNP2 D' r2 FisherExact.P 
rs146159734 rs41304587 1 5.64E-06 1 
rs146159734 rs61745662 1 4.93E-06 1 
rs146159734 rs139949439 1 3.52E-06 1 
rs146159734 rs141748831 1 2.11E-06 1 
rs146159734 rs28477279 1 7.03E-07 1 
rs146159734 rs201461870 1 7.03E-07 1 
rs146159734 rs201638257 1 4.93E-06 1 
rs146159734 rs191015656 1 7.03E-07 1 
rs146159734 rs200100926 NA NA 1 
rs146159734 rs79092403 1 7.03E-07 1 
rs41304587 rs61745662 1 6.58E-06 1 
rs41304587 rs139949439 1 4.70E-06 1 
rs41304587 rs141748831 1 2.82E-06 1 
rs41304587 rs28477279 1 9.39E-07 1 
rs41304587 rs201461870 1 9.39E-07 1 
rs41304587 rs201638257 1 6.58E-06 1 
rs41304587 rs191015656 1 9.39E-07 1 
rs41304587 rs200100926 NA NA 1 
rs41304587 rs79092403 1 9.39E-07 1 
rs61745662 rs139949439 1 4.11E-06 1 
rs61745662 rs141748831 1 2.46E-06 1 
rs61745662 rs28477279 1 8.21E-07 1 
rs61745662 rs201461870 1 8.21E-07 1 
rs61745662 rs201638257 1 5.76E-06 1 
rs61745662 rs191015656 1 8.21E-07 1 
rs61745662 rs200100926 NA NA 1 
rs61745662 rs79092403 1 8.21E-07 1 
rs139949439 rs141748831 1 1.76E-06 1 
rs139949439 rs28477279 1 5.86E-07 1 
rs139949439 rs201461870 1 5.86E-07 1 
rs139949439 rs201638257 1 4.11E-06 1 
rs139949439 rs191015656 1 5.86E-07 1 
rs139949439 rs200100926 NA NA 1 
rs139949439 rs79092403 1 5.86E-07 1 
rs141748831 rs28477279 1 3.51E-07 1 
rs141748831 rs201461870 1 3.51E-07 1 
rs141748831 rs201638257 1 2.46E-06 1 
rs141748831 rs191015656 1 3.51E-07 1 
rs141748831 rs200100926 NA NA 1 
rs141748831 rs79092403 1 3.51E-07 1 
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rs28477279 rs201461870 1 1.17E-07 1 
rs28477279 rs201638257 1 8.21E-07 1 
rs28477279 rs191015656 1 1.17E-07 1 
rs28477279 rs200100926 NA NA 1 
rs28477279 rs79092403 1 1.17E-07 1 
rs201461870 rs201638257 1 8.21E-07 1 
rs201461870 rs191015656 1 1.17E-07 1 
rs201461870 rs200100926 NA NA 1 
rs201461870 rs79092403 1 1.17E-07 1 
rs201638257 rs191015656 1 8.21E-07 1 
rs201638257 rs200100926 NA NA 1 
rs201638257 rs79092403 1 8.21E-07 1 
rs191015656 rs200100926 NA NA 1 
rs191015656 rs79092403 1 1.17E-07 1 
rs200100926 rs79092403 NA NA 1 
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Supplemental Table 4. SNV known or suggestive signals (P<7.0E-06). 
phenotype dbSNPID chr:pos SKATgene snp annotation Ref Alt N EAF beta se direction pval 
Epi low 2 rs12566888 1:156869047 PEAR1 intronic G T 3797 0.094 -0.291 0.040 --- 2.98E-13 
ADP low 1 rs12566888 1:156869047 PEAR1 intronic G T 4047 0.098 -0.271 0.038 --- 1.26E-12 
ADP low 2 rs12566888 1:156869047 PEAR1 intronic G T 3697 0.095 -0.283 0.040 --- 2.53E-12 
Epi hgh 2 rs12566888 1:156869047 PEAR1 intronic G T 3798 0.094 -0.275 0.040 --- 6.15E-12 
Epi low 1 rs12566888 1:156869047 PEAR1 intronic G T 3607 0.096 -0.269 0.041 --- 3.27E-11 
Collagen 1 rs1671152 19:55526345 GP6 nonsynonymous T G 3753 0.835 -0.199 0.033 --+ 1.01E-09 
Collagen 2 rs1671152 19:55526345 GP6 nonsynonymous T G 3753 0.835 -0.198 0.033 --- 1.44E-09 
Collagen 4 rs1671152 19:55526345 GP6 nonsynonymous T G 3742 0.835 -0.194 0.033 --+ 2.71E-09 
ADP high 2 rs12566888 1:156869047 PEAR1 intronic G T 3794 0.095 -0.232 0.040 --- 5.84E-09 
Epi low 1 rs4545476 10:112922409 
exm2249039 
(nearest 
ADRA2A) 
intergenic C T 3607 0.375 -0.144 0.025 --- 1.44E-08 
Collagen 1 rs1613662 19:55536595 GP6 nonsynonymous G A 3753 0.832 -0.181 0.032 --+ 1.82E-08 
Collagen 3 rs1671152 19:55526345 GP6 nonsynonymous T G 3753 0.835 -0.181 0.032 --+ 2.33E-08 
Collagen 2 rs1654413 19:55526359 GP6 nonsynonymous A T 3753 0.820 -0.173 0.032 --- 4.55E-08 
Collagen 1 rs1654413 19:55526359 GP6 nonsynonymous A T 3753 0.820 -0.170 0.031 --+ 6.25E-08 
Collagen 2 rs2304167 19:55527081 GP6 nonsynonymous C T 3753 0.820 -0.170 0.032 --- 6.66E-08 
Epi low 1 rs869244 10:112909105 
exm-rs869244 
(nearest 
ADRA2A) 
intergenic G A 3607 0.330 -0.140 0.026 --- 7.59E-08 
Collagen 2 rs1613662 19:55536595 GP6 nonsynonymous G A 3753 0.832 -0.174 0.032 --- 7.84E-08 
Epi hgh 2 rs10761731 10:65027610 JMJD1C intronic A T 3798 0.428 0.129 0.024 ++- 9.72E-08 
Epi low 2 rs869244 10:112909105 
exm-rs869244 
(nearest 
ADRA2A) 
intergenic G A 3797 0.331 -0.135 0.025 --- 9.77E-08 
Collagen 1 rs2304167 19:55527081 GP6 nonsynonymous C T 3753 0.820 -0.167 0.031 --+ 1.06E-07 
Collagen 4 rs1654413 19:55526359 GP6 nonsynonymous A T 3742 0.820 -0.165 0.031 --+ 1.51E-07 
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Collagen 4 rs1613662 19:55536595 GP6 nonsynonymous G A 3742 0.832 -0.169 0.032 --+ 1.58E-07 
Collagen 4 rs2304167 19:55527081 GP6 nonsynonymous C T 3742 0.820 -0.162 0.031 --+ 2.72E-07 
Epi hgh 2 rs342293 7:106372219 
exm-rs342293 
(nearest 
PIK3CG) 
intergenic C G 3798 0.435 -0.121 0.024 --- 3.24E-07 
Epi low 2 rs342293 7:106372219 
exm-rs342293 
(nearest 
PIK3CG) 
intergenic C G 3797 0.435 -0.121 0.024 --- 3.33E-07 
Epi low 2 rs10761731 10:65027610 JMJD1C intronic A T 3797 0.428 0.123 0.024 ++- 3.35E-07 
Epi low 2 rs4545476 10:112922409 
exm2249039 
(nearest 
ADRA2A) 
intergenic C T 3797 0.377 -0.126 0.025 --- 3.78E-07 
Collagen 3 rs1613662 19:55536595 GP6 nonsynonymous G A 3753 0.832 -0.161 0.032 --+ 5.29E-07 
Epi high 1 rs4909945 11:10673739 MRVI1 nonsynonymous T C 2730 0.659 -0.149 0.030 --- 6.28E-07 
Collagen 3 rs1654413 19:55526359 GP6 nonsynonymous A T 3753 0.820 -0.155 0.031 --+ 7.45E-07 
Epi low 1 rs2914908 5:117982046 
exm2270115 
(nearest 
RPL11-2N5.2) 
intergenic C T 3607 0.490 0.120 0.024 +++ 7.57E-07 
Epi hgh 2 rs4909945 11:10673739 MRVI1 nonsynonymous T C 3798 0.665 -0.126 0.026 --- 7.87E-07 
Epi high 1 rs7940646 11:10669228 MRVI1 intronic T C 2730 0.658 -0.148 0.030 --- 7.88E-07 
ADP high 2 rs6943029 7:155762157 
exm-rs6943029 
(nearest SHH) 
intergenic G A 3794 0.072 0.222 0.046 +++ 1.13E-06 
ADP high 2 rs2263316 6:31421297 HCP5 intergenic A G 3794 0.650 0.123 0.025 +++ 1.15E-06 
Collagen 3 rs2304167 19:55527081 GP6 nonsynonymous C T 3753 0.820 -0.152 0.031 --+ 1.20E-06 
Epi hgh 2 rs7940646 11:10669228 MRVI1 intronic T C 3798 0.664 -0.124 0.025 --- 1.25E-06 
Epi hgh 2 rs10761779 10:65274927 JMJD1C intergenic A G 3798 0.500 0.115 0.024 +++ 1.82E-06 
ADP high 1 rs7940646 11:10669228 MRVI1 intronic T C 3275 0.662 -0.131 0.027 --- 1.84E-06 
Epi hgh 2 rs12355784 10:65121565 JMJD1C intronic C A 3798 0.500 0.113 0.024 +++ 2.54E-06 
Epi hgh 2 rs869244 10:112909105 
exm-rs869244 
(nearest 
ADRA2A) 
intergenic G A 3798 0.330 -0.120 0.025 --- 2.61E-06 
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Epi hgh 2 rs4545476 10:112922409 
exm2249039 
(nearest 
ADRA2A) 
intergenic C T 3798 0.377 -0.116 0.025 --- 2.61E-06 
Epi low 2 rs10761779 10:65274927 JMJD1C intergenic A G 3797 0.501 0.113 0.024 +++ 2.67E-06 
ADP high 1 rs4909945 11:10673739 MRVI1 nonsynonymous T C 3275 0.662 -0.129 0.027 --- 2.72E-06 
ADP high 1 rs1052763 22:19119751 TSSK2 nonsynonymous C T 3275 0.183 -0.154 0.033 --- 3.08E-06 
Epi low 2 rs4909945 11:10673739 MRVI1 nonsynonymous T C 3797 0.665 -0.118 0.025 --- 3.71E-06 
Epi low 2 rs12355784 10:65121565 JMJD1C intronic C A 3797 0.500 0.110 0.024 +++ 4.26E-06 
Collagen 3 rs7832232 8:38469303 
exm-rs7832232 
(nearest 
RNF5P1) 
intergenic A G 3753 0.474 0.109 0.024 +++ 4.48E-06 
Collagen 4 rs7832232 8:38469303 
exm-rs7832232 
(nearest 
RNF5P1) 
intergenic A G 3742 0.474 0.109 0.024 +++ 4.70E-06 
Epi low 1 rs144150699 3:54952554 LRTM1 nonsynonymous G C 3058 0.001 2.073 0.455 =++ 5.26E-06 
ADP low 1 rs4909945 11:10673739 MRVI1 nonsynonymous T C 4047 0.668 -0.113 0.025 --- 5.81E-06 
ADP low 1 rs7940646 11:10669228 MRVI1 intronic T C 4047 0.667 -0.112 0.025 --- 6.28E-06 
Epi low 2 rs7940646 11:10669228 MRVI1 intronic T C 3797 0.664 -0.115 0.025 --- 6.29E-06 
Epi low 2 rs115780313 1:34254272 CSMD2 nonsynonymous T C 3797 0.002 1.300 0.288 ++= 6.45E-06 
Collagen 1 rs9267673 6:31883679 C2 intronic C T 3753 0.114 -0.173 0.039 --- 6.88E-06 
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Supplemental Table 5. SNV associations confirming prior reported genome-wide significant findings
4
. 
 
gene/region chr:pos dbSNPid 
translational 
effect 
Phenotype N AF beta p-value direction 
PEAR1 1:156869047 rs12566888 intronic 
ADP low1 4047 0.098 -0.2708 1.26E-12 --- 
ADP low2 3697 0.095 -0.2828 2.53E-12 --- 
ADP high2 3794 0.095 -0.2317 5.84E-09 --- 
Epi low1 3607 0.096 -0.2688 3.27E-11 --- 
Epi low2 3797 0.094 -0.2913 2.98E-13 --- 
Epi high2 3798 0.094 -0.2751 6.15E-12 --- 
JMJD1C 10:65027610 rs10761731 intronic 
Epi low2 3797 0.428 0.1231 3.35E-07 ++- 
Epi high2 3798 0.428 0.1290 9.72E-08 ++- 
ADRA2A 10:112922409 rs4545476 intergenic 
Epi low1 3607 0.375 -0.1437 1.44E-08 --- 
Epi low2 3797 0.377 -0.1256 3.78E-07 --- 
ADRA2A 10:112909105 rs869244 intergenic 
Epi low1 3607 0.330 -0.1400 7.59E-08 --- 
Epi low2 3797 0.331 -0.1354 9.77E-08 --- 
GP6 19:55526345 rs1671152 nonsynonymous 
Collagen 1 3753 0.835 -0.1988 1.01E-09 --+ 
Collagen 2 3753 0.835 -0.1979 1.44E-09 --- 
Collagen 5 3753 0.835 -0.1810 2.33E-08 --+ 
Collagen 10 3742 0.835 -0.1938 2.71E-09 --+ 
PIK3CG 
region 
7:106372219 rs342293 intergenic 
Epi high2 3798 0.435 -0.1212 3.24E-07 --- 
Epi low2 3797 0.435 -0.1208 3.33E-07 --- 
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Supplemental Table 6. Power analysis for 4,000 individuals with family structure. We used 
SOLAR
32 
to simulate phenotypes conditional on the observed family structures in the FHS 
sample. The phenotypes were simulated to have variance of 1 and polygenic heritability of 0.25. 
We considered the QTL (additive model) with MAF of 0.01, 0.05, 0.1, 0.2, 0.3 and 0.4, and QTL 
variance of 0.0025, 0.005, 0.0075 and 0.01. 1,000 of replicates were used to estimate power for 
each considered scenario. Simulated phenotypes were analyzed using a linear mixed effects 
model implemented in the lmekin function from the coxme R package where a relationship 
coefficient matrix was used to account for familial correlation. 
maf qtl_var power  
0.01 0.0025 0.03 
0.01 0.005 0.25 
0.01 0.0075 0.577 
0.01 0.01 0.813 
0.05 0.0025 0.03 
0.05 0.005 0.243 
0.05 0.0075 0.595 
0.05 0.01 0.848 
0.1 0.0025 0.023 
0.1 0.005 0.232 
0.1 0.0075 0.601 
0.1 0.01 0.863 
0.2 0.0025 0.022 
0.2 0.005 0.23 
0.2 0.0075 0.598 
0.2 0.01 0.843 
0.3 0.0025 0.02 
0.3 0.005 0.227 
0.3 0.0075 0.594 
0.3 0.01 0.861 
0.4 0.0025 0.027 
0.4 0.005 0.244 
0.4 0.0075 0.586 
0.4 0.01 0.856 
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Supplemental Figure 1. Cohort level and meta-analysis QQ plots and genomic control values 
for single SNP and gene-based tests. 
1. Framingham Heart Study 
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2. GeneSTAR 
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3. PAPI 
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4. Single SNP meta-analysis 
 
 
Page 41 of 46
URL: http://mc.manuscriptcentral.com/cpla E-mail: P.Harrison.1@bham.ac.uk
Platelets
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
 
 
Page 42 of 46
URL: http://mc.manuscriptcentral.com/cpla E-mail: P.Harrison.1@bham.ac.uk
Platelets
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
5. VT meta-analysis 
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